INCR May 2024 2.500 call
| Previous close | 0.6500 |
| Open | 0.7000 |
| Bid | 0.5500 |
| Ask | 0.6500 |
| Strike | 2.50 |
| Expiry date | 2024-05-17 |
| Day's range | 0.6500 - 0.7000 |
| Contract range | N/A |
| Volume | |
| Open interest | 78 |
Business WireInterCure Announces FY2023 Results: Revenue of NIS 356 million and Adjusted EBITDA of NIS 61 million
NEW YORK & HERZLIYA, Israel, May 01, 2024--InterCure Ltd. (NASDAQ: INCR) (TASE: INCR) ("InterCure" or the "Company") today announced results for the full year ending December 31, 2023. All amounts are expressed in New Israeli Shekels (NIS), unless otherwise noted.
Business WireInterCure Announces Preliminary Estimated 2023 Revenue of NIS 351 million and EBITDA of over NIS 50 million
NEW YORK & HERZLIYA, Israel, April 01, 2024--InterCure Ltd. (NASDAQ: INCR) (TASE: INCR) ("InterCure" or the "Company") today announced preliminary results for the full year of 2023. All amounts are expressed in New Israeli Shekels (NIS), unless otherwise noted.
Business WireInterCure Congratulates Germany on Cannabis Reform, Expanding its Global Footprint
NEW YORK & HERZLIYA, Israel, March 22, 2024--InterCure Ltd. (NASDAQ: INCR) (TASE: INCR) (dba Canndoc) ("InterCure" or the "Company"), the leading medical cannabis company outside of North America, is thrilled to congratulate The Federal Republic of Germany for the passing of the "CannG" Cannabis Act, which is expected to take effect on April 1, 2024. On the backdrop of this monumental development, InterCure expects to launch a series of products in Germany in the coming months.
